NASDAQ:NVCN Neovasc Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neovasc Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.05 -0.04 (-0.66%) (As of 07/1/2022 08:00 PM ET) Add Compare Share Today's Range$6.05▼$6.0550-Day Range$4.90▼$160.5052-Week Range$4.59▼$23.25Volume6,500 shsAverage Volume15,761 shsMarket Capitalization$16.38 millionP/E RatioN/ADividend YieldN/APrice Target$125.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Neovasc MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,966.1% Upside$125.00 Price TargetShort InterestHealthy0.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.67 out of 5 starsMedical Sector885th out of 1,428 stocksSurgical & Medical Instruments Industry90th out of 138 stocks 3.5 Analyst's Opinion Consensus RatingNeovasc has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $125.00, Neovasc has a forecasted upside of 1,966.1% from its current price of $6.05.Amount of Analyst CoverageNeovasc has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.14% of the float of Neovasc has been sold short.Short Interest Ratio / Days to CoverNeovasc has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neovasc has recently decreased by 21.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeovasc does not currently pay a dividend.Dividend GrowthNeovasc does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVCN. Previous Next 2.5 News and Social Media Coverage News SentimentNeovasc has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Neovasc this week, compared to 2 articles on an average week.Search Interest1 people have searched for NVCN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Neovasc to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neovasc insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 2.42% of the stock of Neovasc is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Neovasc is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neovasc is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeovasc has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter. Email Address About Neovasc (NASDAQ:NVCN) StockNeovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.Read More NVCN Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comNeovasc (NASDAQ:NVCN) Coverage Initiated by Analysts at StockNews.comJune 28, 2022 | finance.yahoo.comWorldwide Cardiovascular Implants Industry to 2027 - Featuring Biotronik, Abbott Laboratories and AMG International Among Others - Yahoo FinanceJuly 4, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. June 23, 2022 | americanbankingnews.comNeovasc (NASDAQ:NVCN) Receives New Coverage from Analysts at StockNews.comJune 14, 2022 | americanbankingnews.comNeovasc (NASDAQ:NVCN) Share Price Passes Below 50 Day Moving Average of $10.30June 14, 2022 | americanbankingnews.comStockNews.com Begins Coverage on Neovasc (NASDAQ:NVCN)June 8, 2022 | globenewswire.comNeovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference - GlobeNewswireJune 8, 2022 | finance.yahoo.comNeovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference - Yahoo FinanceJuly 4, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. May 27, 2022 | globenewswire.comRevenue of Heart Valve Devices Market Estimated at US$ 26.3 Mn by 2031, TMR Study - GlobeNewswireMay 27, 2022 | benzinga.comTranscatheter Heart Valve Replacement Market is Predicted to Witness Huge Growth of USD 11.63 billion by 2027 : Fior Markets - BenzingaMay 23, 2022 | streetinsider.comNeovasc to Participate in HC Wainwright Global Investment Conference - StreetInsider.comMay 18, 2022 | benzinga.comNeovasc Regains Compliance with Nasdaq Minimum Bid Price Rule - Benzinga - BenzingaMay 16, 2022 | streetinsider.comNeovasc Regains Compliance with Nasdaq Minimum Bid Price Rule - StreetInsider.comMay 13, 2022 | apnews.comNeovasc: Q1 Earnings Snapshot - The Associated Press - en EspañolMay 11, 2022 | nasdaq.comAspira (AWH) Reports Q1 Loss, Misses Revenue Estimates - NasdaqMay 10, 2022 | nasdaq.com908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates - NasdaqMay 9, 2022 | nasdaq.comLENSAR, Inc. (LNSR) Reports Q1 Loss, Tops Revenue Estimates - NasdaqMay 5, 2022 | finance.yahoo.comAshvattha Therapeutics to Present at UBS Global Healthcare Conference 2022 - Yahoo FinanceMay 2, 2022 | benzinga.comStocks That Hit 52-Week Highs On Monday - Benzinga - BenzingaMay 1, 2022 | streetinsider.comNeovasc to Report First Quarter Financial Results on May 12, 2022 - StreetInsider.comApril 28, 2022 | benzinga.comNeovasc Offers Comment On 'European Heart Journal' Publication: Notes 'Report demonstrates objective impr - BenzingaApril 28, 2022 | globenewswire.comNeovasc Comments on European Heart Journal Publication - GlobeNewswireApril 28, 2022 | finance.yahoo.comNeovasc Comments on European Heart Journal PublicationApril 27, 2022 | globenewswire.comNeovasc Announces Effective Date of Share Consolidation - GlobeNewswireApril 27, 2022 | finance.yahoo.comNeovasc Announces Effective Date of Share ConsolidationApril 20, 2022 | globenewswire.comNeovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference - GlobeNewswireSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCN CUSIPN/A CIK1399708 Webwww.neovasc.com Phone(604) 270-4344Fax604-270-4384Employees49Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/04/2022Next Earnings (Estimated)8/09/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$125.00 High Stock Price Forecast$125.00 Low Stock Price Forecast$125.00 Forecasted Upside/Downside+1,966.1%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($12.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,890,000.00 Net Margins-1,192.20% Pretax Margin-1,211.86% Return on Equity-50.69% Return on Assets-39.37% Debt Debt-to-Equity Ratio0.27 Current Ratio12.88 Quick Ratio12.50 Sales & Book Value Annual Sales$2.55 million Price / Sales6.42 Cash FlowN/A Price / Cash FlowN/A Book Value$19.31 per share Price / Book0.31Miscellaneous Outstanding Shares2,707,000Free FloatN/AMarket Cap$16.38 million OptionableNot Optionable Beta2.24 Neovasc Frequently Asked Questions Should I buy or sell Neovasc stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Neovasc stock. View analyst ratings for Neovasc or view top-rated stocks. What is Neovasc's stock price forecast for 2022? 1 equities research analysts have issued 12 month price objectives for Neovasc's stock. Their NVCN stock forecasts range from $125.00 to $125.00. On average, they anticipate Neovasc's stock price to reach $125.00 in the next year. This suggests a possible upside of 1,966.1% from the stock's current price. View analysts' price targets for Neovasc or view top-rated stocks among Wall Street analysts. How has Neovasc's stock price performed in 2022? Neovasc's stock was trading at $11.7150 at the start of the year. Since then, NVCN stock has decreased by 48.4% and is now trading at $6.05. View the best growth stocks for 2022 here. When is Neovasc's next earnings date? Neovasc is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Neovasc. How were Neovasc's earnings last quarter? Neovasc Inc. (NASDAQ:NVCN) released its quarterly earnings data on Thursday, May, 12th. The medical equipment provider reported ($3.01) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by $1.76. The medical equipment provider earned $0.61 million during the quarter, compared to analyst estimates of $0.80 million. Neovasc had a negative net margin of 1,192.20% and a negative trailing twelve-month return on equity of 50.69%. View Neovasc's earnings history. When did Neovasc's stock split? How did Neovasc's stock split work? Neovasc's stock reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 4 shares after the split. Who are Neovasc's key executives? Neovasc's management team includes the following people: Mr. Fredericus A. Colen, Pres, CEO & Director (Age 70, Pay $2.59M)Mr. Christopher Clark B.A., BA (Honours), C.A., CA, PgD, CFO & Corp. Sec. (Age 50, Pay $1.12M)Mr. William Reed Little, Chief Operating Officer (Age 51, Pay $1.2M)Mr. John Christopher Panton, Chief Quality Officer (Age 55, Pay $399.7k)Sarah Marie-Hodgson Gallagher, VP of Clinical Affairs Who are some of Neovasc's key competitors? Some companies that are related to Neovasc include Vapotherm (VAPO), Nemaura Medical (NMRD), Pro-Dex (PDEX), Titan Medical (TMDI), Daxor (DXR), TransEnterix (TRXC), Modular Medical (MODD), Biostage (BSTG), Pulse Biosciences (PLSE), Isoray (ISR), Isoray (ISR), SANUWAVE Health (SNWV), GlucoTrack (GCTK), Integrity Applications (IGAP) and enVVeno Medical (NVNO). View all of NVCN's competitors. What other stocks do shareholders of Neovasc own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Protalix BioTherapeutics (PLX), Palatin Technologies (PTN), (XXII) and Amarin (AMRN). What is Neovasc's stock symbol? Neovasc trades on the NASDAQ under the ticker symbol "NVCN." How do I buy shares of Neovasc? Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neovasc's stock price today? One share of NVCN stock can currently be purchased for approximately $6.05. How much money does Neovasc make? Neovasc (NASDAQ:NVCN) has a market capitalization of $16.38 million and generates $2.55 million in revenue each year. The medical equipment provider earns $-24,890,000.00 in net income (profit) each year or ($12.00) on an earnings per share basis. How many employees does Neovasc have? Neovasc employs 49 workers across the globe. How can I contact Neovasc? Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The official website for Neovasc is www.neovasc.com. The medical equipment provider can be reached via phone at (604) 270-4344, via email at investors@neovasc.com, or via fax at 604-270-4384. This page (NASDAQ:NVCN) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here